Study on the Expression Level of Serum GP73 and SMAD2 and Clinical Value in Patients with Endometriosis
10.3969/j.issn.1671-7414.2025.01.023
- VernacularTitle:子宫内膜异位症患者血清GP73和SMAD2表达水平及临床价值研究
- Author:
Hui DING
1
;
Xuemei SU
1
;
Rong ZHANG
1
Author Information
1. 新疆军区总医院妇产科,乌鲁木齐 830000
- Publication Type:Journal Article
- Keywords:
golgi protein 73;
SMAD2;
endometriosis
- From:
Journal of Modern Laboratory Medicine
2025;40(1):122-126,131
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression and clinical significance of serum Golgi protein 73 (GP73) and SMAD family member 2 (SMAD2)in endometriosis. Methods From March 2022 to September 2023,175 patients with endometriosis who visited Xinjiang Military Region General Hospital were collected as the observation group. According to the staging of endometriosis,patients were separated into mild group (stage Ⅰ,n=61),moderate group (stage Ⅱ,n=52 ) and severe group (stage Ⅲ-Ⅳ,n=62). The healthy group comprised 55 healthy individuals who underwent medical examinations from December 2020 to December 2022 at Xinjiang Military Region General Hospital. ELISA was applied to detect serum GP73 and SMAD2 levels,the general data of the observation group and the control group were compared. Logistic regression was used to analyze the relevant factors affecting the occurrence of endometriosis,the Pearson method was applied to investigate the correlation between serum GP73 and SMAD2 levels in patients with endometriosis.ROC curves were used to assess the diagnostic value of serum GP73,SMAD2 levels and their combination in patients with EMT. Results The presence or absence of dysmenorrhea and irregular menstruation was compared between the two groups,and the differences were statistically significant (x2=17.633,39.268,all P<0.001). Serum GP73 (73.68±19.23 ng/ml),SMAD2 (42.27±9.61 mg/L) expression levels in the observation group were higher than those in the control group (58.61±13.27 ng/ml,35.26±6.37 mg/L),and the differences were statistically significant (t=8.327,7.845,all P<0.05). GP73 (59.79±17.26,73.73±18.17,87.29±22.05ng/ml) and SMAD2 (35.18±7.39,39.97±9.45,51.17±11.96mg/L) increased sequentially in the mild,moderate and severe groups,and the differences were statistical significance (F=31.067,42.866,all P<0.05). Pearson analysis showed serum GP73 levels were positively correlated with SMAD2 levels in EMT patients (r=0.427,P<0.001).Multifactorial Logistic regression analysis showed that irregular menstruation,dysmenorrhea,serum GP73[OR(95％CI):2.035 (1.208～3.428)],SMAD2[OR(95％CI):1.972 (1.284～3.029)]levels were risk factors for the development of EMT in patients (all P<0.05). The AUC(95％CI) for the combined diagnosis of EMT by serum GP73 and SMAD2 was 0.821 (0.776～0.861),which was higher than that of serum GP73 and SMAD2 alone[0.763 (0.714～0.807),0.708 (0.656～0.756)],respectively,and the differences were statistically significant (Z=3.121,4.346,all P<0.05). Conclusion Elevated serum GP73 and SMAD2 levels in EMT patients are all related to the extent of the patient's condition and have some diagnostic value for EMT.
